RxDoctor Payments DataLook up a doctor →

James Noriega, DPM

Foot & Ankle Surgery · Lafayette, LANPI 1962538678

Payments from drug & device makers

$10,837in general payments, 2019–2025

Across 290 payments — averaging $37.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$2K
  • Paratek Pharmaceuticals, Inc.$2K
  • Medical Device Business Services, Inc.$1K
  • Bioventus LLC$925
  • Treace Medical Concepts, Inc.$820
  • Convatec Inc.$641
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$1001%
  • Travel & lodging$2,28421%
  • Food & beverage$8,45378%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,837 in reported general payments places this provider in the 85th percentile of 92 foot & ankle surgery providers in Louisiana.

See all foot & ankle surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$212,424
Medicare patients
712
Services billed
2,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate12$96,755
SantylCollagenase Clostridium Hist.22$11,096
Lidocaine-PrilocaineLidocaine/Prilocaine30$3,345
Gabapentin94$1,852
Betamethasone Dipropionate35$1,687
Ketoconazole52$1,638
Oxycodone Hcl40$1,469
Celecoxib55$957
Diclofenac Sodium40$849
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$712
SsdSilver Sulfadiazine85$676
Ciclopirox22$489
Pregabalin29$369
Silver Sulfadiazine40$365
Clindamycin Hcl65$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$1,558$96,75512 claims
Smith+NephewSantyl$383$11,09622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 foot & ankle surgery providers in Louisiana.

Other foot & ankle surgery in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →